SPX-303 is under clinical development by Sparx Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SPX-303’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SPX-303 overview

SPX-303 is under development for the treatment of advanced or refractory solid tumors, metastatic gastric and colon cancer. It is a a first-in-class anti-LILRB2/PD-L1 bispecific antibody drug candidate. The drug candidate is being developed based on SAILING multi-specific antibody discovery platform. It is administered through intravenous route.

Sparx Therapeutics overview

Sparx Therapeutics is a research-based development stage biopharmaceutical company. The company discovers and develops innovative medicines of highly unmet medical needs. Sparx Therapeutics is headquartered in Mount Prospect, Illinois, the US.

For a complete picture of SPX-303’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.